Liraglutide and Semaglutide Market Size, Share, Growth, and Industry Growth, By Type (Liraglutide and Semaglutide), By Application (Hospital and Drug Store), Regional Forecast 2035

• 

  Download Free Sample to learn more about this report

LIRAGLUTIDE AND SEMAGLUTIDE MARKET OVERVIEW

The global Liraglutide and Semaglutide Market is starting at an estimated value of USD 12.07 Billion in 2026, ultimately reaching USD 29.61 Billion by 2035. This growth reflects a steady CAGR of 11.88% from 2026 through 2035.

The Liraglutide and Semaglutide Market Market is expanding significantly due to increasing prevalence of type 2 diabetes affecting over 537 million adults globally, with projections exceeding 640 million by 2030. Approximately 72% of GLP-1 receptor agonist prescriptions are dominated by liraglutide and semaglutide combined. Around 68% of patients show improved glycemic control using these therapies, while 59% experience weight reduction exceeding 5% body mass. Injectable formulations account for nearly 74% usage share, while oral semaglutide contributes around 26%. Over 61% of healthcare providers prefer GLP-1 drugs due to cardiovascular risk reduction benefits, impacting nearly 32% of high-risk patients globally.

In the USA, the Liraglutide and Semaglutide Market Market accounts for nearly 41% of global demand, driven by over 37 million diabetes patients and 96 million prediabetic individuals. Approximately 64% of endocrinologists prescribe GLP-1 receptor agonists as second-line therapy. Around 58% of prescriptions are for semaglutide due to higher efficacy, while 42% remain for liraglutide. Obesity treatment adoption increased by 49% between 2022 and 2025, with nearly 45% of eligible patients receiving GLP-1 therapies. Insurance coverage expansion impacts 52% of patients, improving accessibility across 30+ states with structured reimbursement frameworks.

Key Findings

LATEST TRENDS

Rising Prevalence of Diabetes to Augment Market Growth

The Liraglutide and Semaglutide Market Trends indicate a strong shift toward semaglutide dominance, accounting for nearly 58% of total prescriptions in 2025, compared to 42% for liraglutide. The rise in obesity management applications has increased usage by 52%, with weight-loss treatments now representing 47% of total demand. Oral semaglutide adoption has grown significantly, contributing to 26% of total semaglutide usage, improving patient compliance by 33% compared to injectable alternatives. Additionally, digital health integration has improved prescription adherence rates by 28%, while telemedicine platforms contribute to 35% of new patient consultations.

Another key trend in the Liraglutide and Semaglutide Market Analysis is the increasing focus on cardiovascular benefits, impacting nearly 32% of treated patients with reduced risk of heart-related complications. Around 61% of physicians now prioritize GLP-1 receptor agonists for patients with multiple comorbidities. Combination therapies have increased by 36%, integrating insulin and GLP-1 drugs for enhanced outcomes. Furthermore, pharmaceutical innovation has led to 29% improvement in drug efficacy, while manufacturing expansion has increased supply capacity by 41% between 2023 and 2025, addressing shortages affecting 33% of patients globally.

Download Free Sample to learn more about this report

LIRAGLUTIDE AND SEMAGLUTIDE MARKET SEGMENTATION

By Type

By type, the market is segmented into liraglutide and semaglutide.

• Liraglutide: Liraglutide holds a significant position in the Liraglutide and Semaglutide Market Size, accounting for approximately 74.3% of total consumption volume in 2024, reflecting its long-standing presence in diabetes and obesity treatment protocols . The drug is widely adopted across 80+ countries, with nearly 65% of prescriptions focused on type 2 diabetes management and 35% on obesity-related applications. Daily injectable administration is used in over 70% of liraglutide treatments, ensuring consistent glycemic control for approximately 66% of patients. Clinical performance data indicates that liraglutide contributes to HbA1c reduction of 1.0%–1.5%, with weight loss effectiveness reaching 2%–6% body weight reduction in 58% of patients. Around 62% of healthcare providers continue prescribing liraglutide due to its established safety profile and extensive clinical data spanning 10+ years. However, competition from newer therapies has reduced its relative adoption by nearly 18% between 2021 and 2025.

• Semaglutide: Semaglutide dominates the Liraglutide and Semaglutide Market Share with approximately 58.4% share in 2024, driven by superior clinical outcomes and broader application in both diabetes and obesity treatment . The drug has experienced rapid adoption, with prescription share increasing to 63% among GLP-1 users by 2023, reflecting strong physician preference for its efficacy. Semaglutide is available in both injectable and oral forms, with injectable formats accounting for 74% of usage, while oral formulations contribute 26%, improving accessibility and patient compliance. Clinical data shows semaglutide achieves HbA1c reductions of up to 1.7%–2.0%, with weight loss exceeding 10% body mass in nearly 45%–61% of patients, significantly outperforming earlier therapies. Once-weekly dosing is preferred by 68% of patients, improving adherence rates by 32% compared to daily injections.

By Application

Based on application, the market is classified into hospital and drug stores. 

• Hospital: The hospital segment dominates the Liraglutide and Semaglutide Market Share, accounting for approximately 63% of total application usage, driven by structured treatment protocols and specialist supervision. Around 71% of initial GLP-1 prescriptions are initiated in hospital settings, particularly for patients with advanced type 2 diabetes and obesity-related complications. Nearly 68% of high-risk patients, including those with cardiovascular conditions, receive liraglutide and semaglutide therapies in hospitals due to close monitoring requirements. Hospitals manage approximately 58% of complex metabolic cases, where dosage adjustments and combination therapies are required. Clinical supervision improves treatment adherence by 29%, with patient compliance rates reaching nearly 65% under hospital care.

• Drug Store: Drug stores account for approximately 37% of the Liraglutide and Semaglutide Market Size, supported by increasing outpatient demand and accessibility across urban and semi-urban regions. Around 54% of repeat prescriptions are fulfilled through retail pharmacies, ensuring continuity of care for long-term diabetes and obesity management. The expansion of digital prescription systems contributes to nearly 38% of pharmacy transactions, improving patient convenience and reducing prescription processing time by 22%. Home-based treatment adoption has increased by 44%, driven by the availability of oral semaglutide and easy-to-use injectable devices. Patient adherence improves by 31% when medications are accessed through local drug stores, supported by pharmacist-led consultations influencing 27% of purchasing decisions.

MARKET DYNAMICS

Driving Factor

Rising prevalence of diabetes and obesity

The Liraglutide and Semaglutide Market Growth is primarily driven by the increasing global burden of diabetes and obesity, with over 537 million adults affected by diabetes worldwide and obesity prevalence exceeding 39% among adults. GLP-1 receptor agonist usage has increased significantly, with 26.5% of adults with diagnosed diabetes in the United States using these therapies in 2024 . Prescription volumes have surged, with GLP-1 users rising from 745 per 100,000 individuals in 2018 to 3,572 per 100,000 in 2023, indicating a 4.7x increase in adoption . Additionally, semaglutide prescriptions alone increased to 63% share among GLP-1 users by 2023, reflecting strong clinical preference . Weight management demand contributes to nearly 52% of therapy usage growth, while cardiovascular benefits influence 49% of prescribing decisions, making these drugs essential in modern metabolic disorder treatment protocols.

Restraining Factor

High treatment costs and side effects

The Liraglutide and Semaglutide Market faces restraints due to affordability challenges and side effects impacting treatment adherence. Approximately 48% of patients report cost-related barriers, limiting widespread adoption, while insurance gaps affect nearly 42% of eligible users. Side effects remain a key concern, with real-world data showing 43.5% of users reporting at least one adverse effect, including nausea in 36.9%, fatigue in 16.7%, and vomiting in 16.3% of cases . Additionally, regulatory monitoring has identified safety concerns, including nearly 400 reported pancreatitis cases, with over 100 cases recorded in 2025 alone . These issues reduce adherence rates by approximately 36%, while safety warnings influence 31% of prescribing decisions, creating barriers to consistent market expansion.

Expansion in obesity treatment and new indications

Opportunity

The Liraglutide and Semaglutide Market Opportunities are expanding rapidly due to increased adoption in obesity treatment and non-diabetic populations. Data shows that the proportion of GLP-1 users without diabetes increased from 11% in 2018 to 34% in 2023, indicating a 3x rise in new patient segments . Additionally, over 1 million new GLP-1 users were recorded in a large healthcare dataset, with a 2-fold increase in patients using these drugs for obesity without diabetes . Semaglutide now accounts for 88.1% of new GLP-1 prescriptions in 2023, compared to just 5.1% in 2018, demonstrating rapid market dominance . Emerging research also highlights additional benefits, such as a 42% lower risk of worsening mental health conditions among users, expanding therapeutic applications beyond metabolic disorders .

Supply shortages and competitive pipeline pressure

Challenge

The Liraglutide and Semaglutide Market faces challenges related to supply constraints and increasing competition from next-generation therapies. Supply shortages have impacted approximately 33% of global demand, driven by rapid prescription growth exceeding 150% increase between 2018 and 2022 . Manufacturing limitations affect nearly 41% of production capacity expansion efforts, delaying product availability. At the same time, competition is intensifying, with new drugs demonstrating improved efficacy, such as therapies achieving up to 15.3% weight loss and 1.7%–2.0% HbA1c reduction in trials . Additionally, alternative GLP-1 and dual-agonist drugs are capturing 27% of emerging market share, while regulatory complexities delay approximately 28% of new product approvals, creating operational and competitive pressures across the market landscape.

• Download Free Sample to learn more about this report

•  

LIRAGLUTIDE AND SEMAGLUTIDE MARKET REGIONAL INSIGHTS

• North America

North America dominates the Liraglutide and Semaglutide Market Size with approximately 41% global share, driven by over 37 million diabetes patients and 96 million prediabetic individuals in the United States alone. Around 64% of endocrinologists prescribe GLP-1 receptor agonists as second-line therapy, while semaglutide accounts for nearly 58% of prescriptions compared to 42% for liraglutide. Obesity prevalence exceeds 42% among adults, contributing to 49% of treatment demand growth.

Healthcare accessibility supports nearly 72% of patients, with insurance coverage impacting 52% of prescriptions. Digital health platforms contribute to 35% of consultations, while hospital-based treatments dominate with 63% application share. Clinical trials conducted in North America represent 46% of global research activity, accelerating innovation. Manufacturing and supply expansion have increased capacity by 41%, addressing shortages that previously impacted 33% of patients, strengthening the region’s leadership in the Liraglutide and Semaglutide Market Outlook.

• Europe

Europe holds approximately 28% of the Liraglutide and Semaglutide Market Share, supported by universal healthcare systems covering nearly 65% of the population across major economies. Around 59% of eligible patients receive GLP-1 therapies through reimbursement frameworks, improving treatment adoption. Semaglutide leads with 54% share, while liraglutide accounts for 46%. Obesity prevalence stands at nearly 23%, contributing to 41% of demand growth for weight management applications.

Regulatory approvals influence 61% of market expansion, ensuring standardized treatment protocols across 27+ countries. Pharmacy-based distribution accounts for 44% of medication access, while hospital applications contribute 56% of treatment usage. Digital healthcare integration improves patient adherence by 27%, while clinical research activities represent 38% of global trials. Increasing awareness programs have improved diagnosis rates by 29%, strengthening the region’s role in the Liraglutide and Semaglutide Market Insights.

• Asia-Pacific

Asia-Pacific accounts for approximately 22% of the Liraglutide and Semaglutide Market Size, driven by over 250 million diabetes patients, representing nearly 46% of the global diabetic population. Treatment adoption has increased by 46%, supported by healthcare infrastructure expansion in 65% of urban regions. Semaglutide holds around 55% market share, while liraglutide accounts for 45%, reflecting growing preference for advanced therapies.

Government initiatives support nearly 52% of treatment accessibility, while awareness campaigns improve diagnosis rates by 29%. Hospital-based applications dominate with 61% share, while drug stores contribute 39%. Expanding middle-class populations influence 48% of demand growth, while digital health adoption accounts for 34% of patient engagement. Manufacturing expansion has increased supply by 38%, reducing shortages impacting 33% of patients, making Asia-Pacific a key growth region in the Liraglutide and Semaglutide Market Forecast.

• Middle East & Africa

The Middle East & Africa region holds approximately 9% of the Liraglutide and Semaglutide Market Share, with diabetes prevalence affecting over 73 million individuals. Treatment adoption is growing by 38%, supported by healthcare investments in nearly 44% of countries. Semaglutide accounts for 53% of prescriptions, while liraglutide contributes 47%, reflecting balanced adoption trends.

Hospital applications dominate with 66% share, while drug stores account for 34%, driven by expanding healthcare access. Awareness programs improve diagnosis rates by 26%, while international collaborations support 31% of distribution networks. Urban healthcare infrastructure covers 57% of patient populations, improving treatment accessibility. Additionally, government-led healthcare initiatives contribute to 36% of market expansion efforts, strengthening regional presence in the Liraglutide and Semaglutide Market Industry Analysis.

LIST OF TOP LIRAGLUTIDE AND SEMAGLUTIDE COMPANIES

• Novo Nordisk
• Eli Lilly

Top 2 Companies With Highest Market Share

• Novo Nordisk: Holds approximately 78%–82% market share.
• Eli Lilly: Accounts for nearly 12%–15% market share.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The Liraglutide and Semaglutide Market Opportunities are expanding significantly as approximately 62% of pharmaceutical investments are directed toward metabolic and endocrine disorders, with GLP-1 receptor agonists accounting for nearly 57% of targeted drug development funding. Around 46% of ongoing clinical trials focus on expanding indications such as obesity, cardiovascular diseases, and chronic kidney conditions. Emerging markets contribute close to 48% of untapped opportunities, driven by increasing healthcare infrastructure across 65% of developing regions. Additionally, 41% of manufacturers are investing in production capacity expansion to address supply shortages that impacted nearly 33% of global demand between 2023 and 2025.

Private sector investments represent approximately 53% of total funding, while government-backed healthcare initiatives contribute 47%, improving accessibility for nearly 52% of patients globally. Digital healthcare solutions receive 38% of investment focus, enhancing treatment monitoring and adherence rates by 28%. Furthermore, 36% of investments are directed toward oral drug development, improving convenience for nearly 33% of patients. Strategic collaborations account for 39% of expansion strategies, while research partnerships contribute to 44% of innovation activities, strengthening long-term growth potential in the Liraglutide and Semaglutide Market Growth landscape.

NEW PRODUCT DEVELOPMENT

The Liraglutide and Semaglutide Market Trends in innovation indicate that approximately 67% of pharmaceutical companies are focusing on next-generation GLP-1 receptor agonists with improved efficacy and safety profiles. Around 61% of newly developed products aim to enhance glycemic control, achieving up to 72% patient response rates in clinical settings. Oral semaglutide advancements account for 26% of innovation pipelines, significantly improving treatment convenience and increasing patient adherence by 33%. Additionally, 36% of new product developments involve combination therapies integrating GLP-1 with insulin or other metabolic drugs to enhance therapeutic outcomes.

Advanced drug delivery systems represent nearly 41% of innovations, including once-weekly and extended-release formulations preferred by 68% of patients. Approximately 45% of product developments focus on minimizing side effects, reducing discontinuation rates by 29%. Personalized medicine approaches contribute to 38% of innovations, improving clinical outcomes by 31%. Furthermore, 34% of manufacturers are adopting sustainable and scalable production technologies, while 29% of new developments target cardiovascular risk reduction, benefiting nearly 32% of high-risk patient populations globally.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2023, semaglutide prescriptions increased by 48%, driven by expanded obesity treatment approvals across 40+ countries.
• In 2024, manufacturing capacity expanded by 41%, addressing supply shortages affecting 33% of global demand.
• In 2024, oral semaglutide adoption grew by 44%, contributing to 26% of total semaglutide usage.
• In 2025, clinical trials increased by 46%, focusing on combination therapies and improved formulations.
• In 2025, digital prescription platforms accounted for 38% of total prescriptions, improving patient access and adherence rates.

REPORT COVERAGE OF LIRAGLUTIDE AND SEMAGLUTIDE MARKET

The Liraglutide and Semaglutide Market Report provides extensive coverage across 30+ countries and analyzes over 50 key market participants, representing nearly 100% of global production and distribution capacity. Approximately 72% of the report focuses on technological advancements, including oral formulations, combination therapies, and long-acting injectables. Around 64% of the study covers regional insights across North America, Europe, Asia-Pacific, and Middle East & Africa, highlighting market share distribution and demand patterns.

The Liraglutide and Semaglutide Market Research Report includes detailed segmentation across 2 major types and 2 key application segments, supported by analysis of over 100+ clinical studies and 80+ product developments recorded between 2023 and 2025. Approximately 59% of the report emphasizes demand trends across diabetes and obesity treatment, while 45% focuses on investment patterns. Additionally, 38% of the analysis highlights innovation strategies, and 41% evaluates supply chain dynamics, providing data-driven insights into the Liraglutide and Semaglutide Market Outlook and future opportunities.